We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+4.15%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$12.2B
AUM Growth
+$1.52B
(+14%)
Cap. Flow
+$1.17B
Cap. Flow
% of AUM
9.66%
Top 10 Holdings %
Top 10 Hldgs %
19.97%
Holding
2,123
New
434
Increased
455
Reduced
367
Closed
827
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$197M |
| 2 |
Alibaba
BABA
|
+$190M |
| 3 |
Amazon
AMZN
|
+$161M |
| 4 |
GoDaddy
GDDY
|
+$135M |
| 5 |
Walt Disney
DIS
|
+$132M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$122M |
| 2 |
Zoetis
ZTS
|
+$96.3M |
| 3 |
iShares MSCI Emerging Markets ETF
EEM
|
+$69.5M |
| 4 |
Cadence Design Systems
CDNS
|
+$64.2M |
| 5 |
ANSS
Ansys
ANSS
|
+$60.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 24.88% |
| 2 | Consumer Discretionary | 23.99% |
| 3 | Technology | 11.1% |
| 4 | Financials | 8.14% |
| 5 | Industrials | 7.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
601
Intrepid Potash
IPI
$477M
| $3.48M | 0.03% |
103,468
+13,570
| +15% | +$473K |
|
602
Bristol-Myers Squibb
BMY
$130B
| $3.47M | 0.03% |
76,526
-60,463
| -44% | -$2.82M |
|
|
UNT
603
DELISTED
UNIT Corporation
UNT
| $3.45M | 0.03% |
388,510
-107,586
| -22% | -$1.25M |
|
604
Ligand Pharmaceuticals
LGND
$5.94B
| $3.45M | 0.03% |
48,419
-41,607
| -46% | -$3.06M |
|
605
Expro Ltd
XPRO
$1.71B
| $3.44M | 0.03% |
104,853
+92,969
| +782% | +$3.36M |
|
|
IVC
606
DELISTED
Invacare Corporation
IVC
| $3.42M | 0.03% |
658,448
-315,026
| -32% | -$2.05M |
|
|
NGHC
607
DELISTED
National General Holdings Corp
NGHC
| $3.4M | 0.03% |
148,330
+60,884
| +70% | +$1.45M |
|
|
ACOR
608
DELISTED
Acorda Therapeutics
ACOR
| $3.39M | 0.03% |
3,683
-1,182
| -24% | -$1.45M |
|
609
Corcept Therapeutics
CORT
$10.1B
| $3.38M | 0.03% |
303,504
+50,523
| +20% | +$563K |
|
610
Qorvo
QRVO
$8.11B
| $3.38M | 0.03% |
50,790
-29,694
| -37% | -$2.06M |
|
|
ARCH
611
DELISTED
Arch Resources, Inc.
ARCH
| $3.38M | 0.03% |
35,862
+1,833
| +5% | +$168K |
|
612
iShares China Large-Cap ETF
FXI
$4.27B
| $3.37M | 0.03% |
78,837
+67,116
| +573% | +$2.87M |
|
|
HABT
613
DELISTED
The Habit Restaurants, Inc. - Class A
HABT
| $3.36M | 0.03% |
320,329
-139,611
| -30% | -$1.52M |
|
|
BEAT
614
DELISTED
BioTelemetry, Inc.
BEAT
| $3.33M | 0.03% |
+69,181
| New | +$3.64M |
|
615
Archrock
AROC
$6.14B
| $3.31M | 0.03% |
312,384
+106,586
| +52% | +$1.05M |
|
|
SDRL
616
DELISTED
Seadrill Limited Common Stock
SDRL
| $3.31M | 0.03% |
795,161
-37,670
| -5% | -$247K |
|
617
Voya Financial
VOYA
$9.06B
| $3.3M | 0.03% |
59,707
-41,554
| -41% | -$2.23M |
|
|
LTRPA
618
DELISTED
Liberty TripAdvisor Holdings, Inc. Series A
LTRPA
| $3.29M | 0.03% |
+265,551
| New | +$3.48M |
|
|
TCF
619
DELISTED
TCF Financial Corporation Common Stock
TCF
| $3.29M | 0.03% |
80,072
-177,926
| -69% | -$7.38M |
|
|
HEES
620
DELISTED
H&E Equipment Services
HEES
| $3.28M | 0.03% |
112,818
-238,508
| -68% | -$6.64M |
|
621
EQT Corp
EQT
$32.2B
| $3.28M | 0.03% |
207,279
-45,406
| -18% | -$871K |
|
622
Rigel Pharmaceuticals
RIGL
$711M
| $3.25M | 0.03% |
124,656
+10,016
| +9% | +$226K |
|
623
Inogen
INGN
$174M
| $3.22M | 0.03% |
48,275
-7,305
| -13% | -$556K |
|
|
IPOA.U
624
DELISTED
Social Capital Hedosophia Holdings Corp.
IPOA.U
| $3.2M | 0.03% |
300,000
| – | – |
|
625
PUT
iShares Russell 2000 Growth ETF
IWO
$14.4B
| $3.19M | 0.03% |
+16,200
| New | +$3.2M |
|
Similar funds
Marshall Wace's Q2 2019 Portfolio in Review
As of Q2 2019, Marshall Wace held 2,123 positions worth $12.2B, up 14% from $10.6B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Marshall Wace deployed $1.17B of net new capital in Q2 2019, opening 434 new positions and adding to 455 existing holdings. Its largest new stake was EPAM Systems: 482,974 shares worth $83.6M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 21% a quarter earlier, followed by Consumer Discretionary and Technology.
On the sell side, the largest reduction was Alphabet (Google) Class A, an estimated $122M trimmed.
- Marshall Wace's largest Q2 2019 buy was EPAM Systems: 482,974 shares worth $83.6M.
- Marshall Wace added most to Boston Scientific in Q2 2019, an estimated $197M increase.
- Marshall Wace's biggest Q2 2019 reduction was Alphabet (Google) Class A, cutting an estimated $122M.
- Marshall Wace fully exited iShares MSCI Emerging Markets ETF in Q2 2019, selling an estimated $69.5M.
- Marshall Wace's ten largest holdings make up 20% of its $12.2B portfolio in Q2 2019.
- Marshall Wace opened 434 new positions and closed 827 in Q2 2019.
- Marshall Wace's portfolio value rose 14% quarter-over-quarter to $12.2B.
Based on Marshall Wace's 13F filing for Q2 2019, filed 14 Aug 2019.